FH至尊

On June 10, Pharm Exec (Pharmaceutical Executive Magazine in the US) announced the Top 50 Global Pharmaceutical Companies in 2022, and Sino Biopharm entered the list for the fourth consecutive year, with a steady rise in ranking to No. 40.  

  Pharm Exec, a well-known professional pharmaceutical magazine in the international pharmaceutical industry, has published the Top 50 list of global pharmaceutical companies for 23 consecutive years. The list is mainly based on the ranking of each pharmaceutical company's sales revenue of prescription drug. Since 2019, Sino Biopharm has entered the list for four consecutive years, and the ranking has steadily increased.  

Emphasis on Innovation, R&D Capabilities and Overall Strength Have Been Widely Recognized at Home and Abroad

  In recent years, Sino Biopharm has always adhered to the mission of "building a leading integrated pharmaceutical company in China that combines innovation and imitation", and insisted on the concept of "technology creates value" to continuously invest resources to build up its independent innovation capability.   In fiscal year 2021, the Group invested RMB 3.82 billion in research and development, up 34.5% year-on-year, accounting for 14.2% of total revenue. The R&D investment in innovative drugs and biologics accounted for over 70%, with the amount invested increasing by approximately 64.7% year-on-year. The R&D investment in the field of anti-tumor accounted for approximately 75%, and the amount invested increased by approximately 71.2% year-on-year.   The increase in investment in innovation and R&D has enabled the Group to achieve fruitful results while gaining attention and recognition from society and peers worldwide for its innovation and R&D capabilities and overall strength.   In 2021, Sino Biopharm ranked No. 2 in the "2021 Top 100 Chinese Pharmaceutical Innovation Enterprises" released by the China Pharmaceutical Enterprise Management Association; the Group was also selected as one of the "2021 Top 10 Most Innovative R&D Companies in China's Listed Pharmaceutical Companies". On the international front, Sino Biopharm was listed in the Fortune 500 China in 2021, while it was ranked 67th in the 2021 Global Top 1000 Pharmaceutical Companies Report published by Torreya, a leading international investment bank.  

 

Continue to Promote Pharmaceutical Innovation and Globalization Layout

  Believing that innovation capability as well as R&D strength is the core competitiveness of an enterprise, Sino Biopharm continues to promote pharmaceutical innovation and R&D. In 2021, Sino Biopharm has obtained a total of 36 marketing approvals, and by the end of 2021, the Group has accumulated a total of 417 products under development with clinical approvals, clinical trials underway and manufacturing declarations.   At present, the Group has set up several research centers in Beijing, Nanjing, Lianyungang, Qingdao and Shanghai, with a total floor area of over 150,000 square meters, a professional and comprehensive R&D team of over 3,000 people, dozens of research platforms and mature R&D technology platforms, and extensive connection and in-depth cooperation with famous research institutions, universities and hospitals at home and abroad.  

CTTQ Production Base   With continuous investment in research and development, the Group now has three innovative drugs approved for marketing. In 2021, the three innovative drugs, Fucovir, Magnesium Isoglycyrrhizinate Injection and Penpulimab monoclonal antibody, with a combined revenue of $6.4 billion, accounting for 24% of total revenue, contributed significantly to the excellent annual performance.   In 2021, the Group's co-developed anti-PD-1 monoclonal antibody drug Penpulimab Injection (trade name: Anicor) was officially approved by the National Medical Products Administration for the treatment of patients with relapsed or refractory (r/r) classic Hodgkin's lymphoma (cHL) after at least second-line systemic chemotherapy, bringing more treatment options to patients. In addition, Anicor's pipeline covers major oncological diseases such as liver cancer, gastric cancer, lung cancer, Hodgkin's lymphoma and nasopharyngeal cancer. In addition to the approved cHL treatment, Anicor has filed two new drug marketing applications in China and one biologics license application in the United States.   In April 2022, the marketing application for a new indication of the Group's self-developed new class 1.1 drug, Anlotinib (trade name: Fucovir), was approved for the treatment of differentiated thyroid cancer, which is the fifth indication approved for the drug in China. It was previously approved in China for the treatment of non-small cell lung cancer, soft tissue sarcoma, small cell lung cancer and medullary thyroid cancer.   While ensuring high product quality in the company's major areas, the company is actively laying out the establishment of innovative R&D platforms, including antibody platforms, ADC drug platforms, mRNA technology platforms, RNAi, AI drug development, etc. For example, it has cooperated with AI drug R&D leaders XtalPi Technology and Insilico to enhance the small molecule drug discovery capability of Sino Biopharm; and built its own next-generation mRNA platform with R&D pipeline including HPV vaccine and COVID-19 vaccine, etc.   In addition, the Group currently has 2 other innovative drugs reported for production, over 50 innovative drugs in various clinical stages and over 60 innovative drug candidates in pre-clinical stage, mainly focusing on anti-tumor, liver disease and respiratory areas. It is expected that by the end of 2024, 10 innovative drugs are expected to be approved for marketing.   In the future, Sino Biopharm will continue to comprehensively advance its three strategic directions of R&D innovation, internationalization and digitalization, and venture into more unmet clinical areas. We will contribute to human's pursuit of a better life.